<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089100</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00142-43</org_study_id>
    <secondary_id>2013/1957</secondary_id>
    <nct_id>NCT02089100</nct_id>
  </id_info>
  <brief_title>Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer</brief_title>
  <acronym>STEREO-SEIN</acronym>
  <official_title>Multicentric Phase III Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Metastatic Breast Cancer in First-line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The previous reported phase I study allows us to prospectively define the optimal total dose&#xD;
      in different metastatic locations (88). However, several questions are still unanswered such&#xD;
      as the adequate timing of the stereotactic body radiation therapy (SBRT) in oligometastatic&#xD;
      disease. Indeed, there are two different oligometastatic states: &quot;de novo&quot;, i.e. occurring at&#xD;
      first metastatic presentation without any previous systemic therapy; and &quot;secondary&quot;, defined&#xD;
      as residual disease after systemic treatment.&#xD;
&#xD;
      The investigators wish to prospectively study the role of metastases SBRT with curative&#xD;
      intent in de novo oligometastatic disease.&#xD;
&#xD;
      This clinical trial would be the first randomized study studying SBRT at onset of the&#xD;
      metastatic disease. If this trial shows a PFS improvement, it will definitively change the&#xD;
      standard of treatment and it will highlight SBRT as a key treatment of metastatic disease. It&#xD;
      will confirm the oligometastasis hypothesis as well as the Simon Norton hypothesis (92).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>evaluated with a minimal follow-up of 3 years in all patients</time_frame>
    <description>events: local recurrence, distant progression of the target metastases, any new metastasis, death of any cause The definition of progression is based on RECIST1.1 criteria. Progression is assessed locally, in any metastasis present at the time of randomization or in any newly diagnosed metastasis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative rate of local failure</measure>
    <time_frame>evaluated with a minimum follow-up of 3 years in all patients.</time_frame>
    <description>assessed with RECIST1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>evaluated with a minimum follow-up of 3 years in all patients</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>stereotactic body radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The SBRT of all metastases should start in maximum 4 weeks after randomization. Beginning of systemic treatment will take place before 2 and 7 days after SBRT completion. All metastases lesions should be treated every 48h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no specific treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no specific treatment to the oligometastatic sites except for palliation (pain, compression, hemorrhage)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy</intervention_name>
    <arm_group_label>stereotactic body radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Systemic treatment</intervention_name>
    <arm_group_label>no specific treatment</arm_group_label>
    <arm_group_label>stereotactic body radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Biopsy proven breast cancer stage IV AJCC TNM&#xD;
&#xD;
          2. Age &gt;18 years&#xD;
&#xD;
          3. WHO status&lt;/=2&#xD;
&#xD;
          4. Hormonal receptors positive breast cancer (IHC)&#xD;
&#xD;
        6. The primary tumor has to have been treated with curative intent (surgery and /or&#xD;
        radiotherapy) 7. No prior treatment for metastatic relapse&#xD;
&#xD;
        It will be accpeted patients which would have begun a treatment in the case where:&#xD;
&#xD;
          -  Hormonotherapy &lt;/= 1 month&#xD;
&#xD;
          -  Chemotherapy &lt;/= 1 cycle 8. a. Metastatic lesions out of previous radiation field 8.&#xD;
             b. Equal or less than 5 metastatic lesions (measurable or not) 8. c. In case of&#xD;
             measurable lesions, each &lt;/=10 cm or &lt;/=500 mL 9. For liver mets:&#xD;
&#xD;
               1. adequate liver function (liver enzyme &lt;3N, bilirubin&lt;30mg/dl, albumin&gt;2.5g/dl)&#xD;
&#xD;
               2. no underlying cirrhosis or hepatitis&#xD;
&#xD;
               3. liver metastase size &lt;/=7cm diameter&#xD;
&#xD;
               4. not adjacent to stomach or small bowel 10. For abdominal mets:&#xD;
&#xD;
               1. Adequate renal function with a creatinine clearance (Cockroft formula) &gt; 60ml/min&#xD;
                  11. Absence of any psychological, familial, sociological or geographical&#xD;
                  condition with a potential to hamper compliance with the study protocol and&#xD;
                  follow-up schedule 12. Life expectancy &gt; 3 months 13. Affiliated to Health&#xD;
                  Insurance regimen 14. Written and signed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Triple negative breast cancer 3. Prior systemic treatment in metastatic setting&#xD;
        (endocrine therapy, chemotherapy, targeted therapies, radionuclide) 4. Brain metastases 5.&#xD;
        In spinal cord mets:&#xD;
&#xD;
          1. More than 3 consecutive and contagious spinal segments involved by tumor&#xD;
&#xD;
          2. Neurological examination prior randomization &gt; 1 week&#xD;
&#xD;
          3. Inability to tolerate treatment (unable to lie flat)&#xD;
&#xD;
          4. Treated with radionuclide/systemic chemotherapy within 30 days before SBRT&#xD;
&#xD;
          5. Significant or progressive neurological deficit&#xD;
&#xD;
          6. More than 25% spinal canal compromise&#xD;
&#xD;
          7. Malignant epidural spinal cord compression or cauda equina syndrome&#xD;
&#xD;
          8. Spine instability or neurological deficit resulting from bony compression of neural&#xD;
             structures 6. Scleroderma or connective tissue disease as a contraindication to&#xD;
             radiotherapy 7. Pregnancy or breast feeding period&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Céline BOURGIER, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Céline BOURGIER, MD</last_name>
    <phone>04 67 61 25 19</phone>
    <phone_ext>+33</phone_ext>
    <email>celine.bourgier@icm.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cédric Parlavecchio</last_name>
    <phone>01 42 11 38 61</phone>
    <phone_ext>+33</phone_ext>
    <email>cedric.parlavecchio@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cedric Parlavecchio</last_name>
      <phone>0142113861</phone>
      <phone_ext>+33</phone_ext>
      <email>cedric.parlavecchio@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Céline Bourgier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>July 20, 2018</last_update_submitted>
  <last_update_submitted_qc>July 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

